Codexis, Inc. (CDXS)
NASDAQ: CDXS · Real-Time Price · USD
4.780
+0.060 (1.27%)
Dec 3, 2024, 1:58 PM EST - Market open
Codexis Revenue
Codexis had revenue of $12.83M in the quarter ending September 30, 2024, with 38.33% growth. This brings the company's revenue in the last twelve months to $64.45M, down -12.86% year-over-year. In the year 2023, Codexis had annual revenue of $70.14M, down -49.39%.
Revenue (ttm)
$64.45M
Revenue Growth
-12.86%
P/S Ratio
5.16
Revenue / Employee
$370,379
Employees
174
Market Cap
388.99M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 70.14M | -68.45M | -49.39% |
Dec 31, 2022 | 138.59M | 33.84M | 32.30% |
Dec 31, 2021 | 104.75M | 35.70M | 51.69% |
Dec 31, 2020 | 69.06M | 598.00K | 0.87% |
Dec 31, 2019 | 68.46M | 7.86M | 12.98% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Cross Country Healthcare | 1.45B |
Amylyx Pharmaceuticals | 196.49M |
Voyager Therapeutics | 163.78M |
CVRx, Inc. | 47.26M |
MaxCyte | 45.60M |
Silence Therapeutics | 21.77M |
Fate Therapeutics | 13.45M |
Nano-X Imaging | 10.68M |
CDXS News
- 13 days ago - Codexis to Participate in Piper Sandler 36th Annual Healthcare Conference - GlobeNewsWire
- 18 days ago - Codexis Unveils Pioneering Enzymatic Synthesis Data to Enable the Future Manufacturing of RNAi Therapeutics - GlobeNewsWire
- 20 days ago - Codexis Announces Appointment of Raymond De Vré, PhD, to Board of Directors - GlobeNewsWire
- 21 days ago - Codexis TIDES Europe Presentations to Feature Next Step in Evolution of Enzymatic Synthesis for RNAi Therapeutics - GlobeNewsWire
- 24 days ago - Codexis Announces New Employment Inducement Grants - GlobeNewsWire
- 4 weeks ago - Codexis to Participate in Upcoming Healthcare Conferences - GlobeNewsWire
- 4 weeks ago - Codexis, Inc. (CDXS) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Codexis Announces Three siRNA Manufacturing Data Presentations at TIDES Europe Annual Meeting - GlobeNewsWire